



ISSN 0975-413X
CODEN (USA): PCHHAX

Der Pharma Chemica, 2016, 8(8):161-164
(<http://derpharmachemica.com/archive.html>)

L-Proline catalyzed one pot synthesis of novel 1,4-dihydro pyridine derivatives

A. V. Hanumantha Rao, A. Tejeswara Rao, V. Lakshman Rao and A. Jaya Shree*

Centre for Chemical Sciences and Technology, IST, Jawaharlal Nehru Technological University Hyderabad,
Kukatpally, Hyderabad, T. S, India-500 085

ABSTRACT

Multi component, one pot synthesis of diethyl/ dimethyl 4-(2-butyl-4-chloro-1H-imidazol-5-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylate derivatives **3(a-f)** form the condensation of N-alkyl-2-butyl-4-chloro-1H-imidazole-5-carbaldehydes **1(a-c)**, methyl/ethyl acetoacetate (**2**), ammonium carbonate has been described using L-proline as a environmentally benign catalyst. L-proline catalyzed reaction provides a green and inexpensive preparation method for synthesis of above compounds.

Keyword: N-alkyl-2-butyl-4-chloro-1H-imidazole-5-carbaldehydes, ethylaceto acetate, green synthesis, L-proline, 1,4-dihydropyridines.

INTRODUCTION

In 1882, Arthur Hantzsch [1] described first synthesis of 1,4-dihydro pyridine derivatives, which exhibit significant pharmacological properties such as vasodilator, anti-hypertensive, anti-tumor, anti-mutagenic and anti diabetic agents [2]. DHPs also used in the treatment of cardio vascular disease as calcium channel blockers [3]. More than fifteen commercially available important drugs like felodipine [4], amlodipine [5], nifedifine [6] containing the 1,4-dihydro pyridine as common parent nucleus. Literature survey reveals that several attempts have made to improve the hantzsch reaction using various alternative catalysts and greener methodologies. Use of various reagents like [TBA]₂[W₆O₁₉] [7], Yb(OTf)₃ [8], MgO [9], PEG [10] have its own merits and demerits with respect to reaction time and yields. Consequently, there is scope for further work towards mild conditions and better yields.

As a part of our research for new biological active heterocyclic systems relating to 1,4-DHP derivatives, we report herein the one pot synthesis of novel 1,4-dihydro pyridine derivatives using L-proline as catalyst, which is efficient, bifunctional, eco-friendly and useful in several organic transformations[11,12] .

MATERIALS AND METHODS

Chemistry

Melting points are uncorrected and are determined in open capillary tubes in sulphuric acid bath. TLC was performed on silica gel-G and spotting was done using iodine or UV light. IR spectra were recorded using Perkin-Elmer 1000 instrument in KBr phase, ¹H NMR on VARIAN 400 MHz instrument, Mass spectra on Agilent-LC-MS instrument giving only M⁺+1 or M⁺-1 values.

General preparation of compounds 3(a-f) under conventional method

A mixture of **1** (2.5 gm, 13.4 mmol), ethylacetoacetate (3.84 gm, 29 mmol), ammonium acetate (1.07gm, 14 mmol) in the presence of catalytic amount of acetic acid (3 mL) in ethanol (40 mL) for 8–10 hr at refluxing temperature. At the end of this period, a white coloured solid separated out and was filtered, washed and dried to obtain crude **3(a-f)**. The crude product that obtained was then purified by column chromatography (ethyl acetate: hexane, 95:5 to 5:95).

General preparation of compounds 3(a-f) using L-proline

A mixture of **1** (2.5 gm, 13.4 mmol), ethyl acetoacetate (3.84 gm, 29 mmol), ammonium acetate (1.07gm, 14 mmol) in the presence of catalytic amount of L-proline (0.8 mol%) in ethanol (40 mL) for 4–5 hr at room temperature. At the end of this period, a white coloured solid separated out and was filtered, washed and dried to obtain crude **3(a-f)**. The crude product that obtained was then purified by column chromatography (ethyl acetate: hexane, 95:5 to 5:95).

Table-1 Synthesis of 1,4 di hydro pyridine derivatives 3(a-f)

Entry	Substrates	Catalyst	Compounds	% Of yield	Time (hr)	Temperature	M.P.
1a 2a	R=H R ¹ =CH ₃	L-proline	3a	94	4	28 ± 2 °C	210 °C
1b 2a	R=CH ₃ R ¹ =CH ₃	L-proline	3b	96	4	28 ± 2 °C	48 °C
1c 2a	R=methyl sulfonyl R ¹ =CH ₃	L-proline	3c	93	5	28 ± 2 °C	39 °C
1a 2b	R=H R ¹ =C ₂ H ₅	L-proline	3d	92	4	28 ± 2 °C	220 °C
1b 2b	R=CH ₃ R ¹ =C ₂ H ₅	L-proline	3e	91	5	28 ± 2 °C	49 °C
1c 2b	R=methyl sulfonyl R ¹ =C ₂ H ₅	L-proline	3f	94	6	28 ± 2 °C	38 °C
1a 2a	R=H R ¹ =CH ₃	Acetic acid	3a	88	7	78 ± 2 °C	212 °C
1b 2a	R=CH ₃ R ¹ =CH ₃	Acetic acid	3b	86	7	78 ± 2 °C	46 °C
1c 2a	R=methyl sulfonyl R ¹ =CH ₃	Acetic acid	3c	90	8	78 ± 2 °C	39 °C
1a 2b	R=H R ¹ =C ₂ H ₅	Acetic acid	3d	85	7	78 ± 2 °C	223 °C
1b 2b	R=CH ₃ R ¹ =C ₂ H ₅	Acetic acid	3e	88	8	78 ± 2 °C	47 °C
1c 2b	R=methyl sulfonyl R ¹ =C ₂ H ₅	Acetic acid	3f	87	8	78 ± 2 °C	38 °C

Diethyl-4-(2-butyl-4-chloro-1H-imidazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-di carboxylate (3a)

White solid; yield 85%, m. p. 210 °C; IR: 3336 (broad, -NH-), 1657-1669 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, CDCl₃): δ_{ppm} 0.86-0.90 (t, 3H, -CH₃), 1.23-1.31 (t, 6H, 2 × CH₃), 1.33-1.37 (m, 2H, -CH₂), 1.62 (m, 2H, -CH₂), 2.32 (s, 6H, 2 × CH₃), 2.74 (t, 2H, Ar-CH₂), 4.22 (q, 4H, 2 × CH₂), 5.03 (s, 1H, Ar-H), 6.42 (s, 1H, -NH), 7.2 (s, 1H, -NH) MS (ESI) *m/z* 409.1 [M]⁺. Anal. Calcd for C₂₀H₂₈ClN₃O₄: C, 58.60; H, 6.89; N, 10.25. Found: C, 58.49; H, 6.77; N, 10.16%.

Diethyl-4-(2-butyl-4-chloro-1-methyl-1H-imidazol-5-yl)-2, 6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (3b)

White solid; yield 88%, m. p. 48 °C; IR: 3022-2847 cm⁻¹ (broad, -NH-), 1672 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, CDCl₃): δ_{ppm} 0.86-0.90 (t, 3H, -CH₃), 1.23-1.31 (t, 6H, 2 × CH₃), 1.33-1.37 (m, 2H, -CH₂), 1.62 (m, 2H, -CH₂), 2.32 (s, 6H, 2 × CH₃), 2.74 (t, 2H, Ar-CH₂), 4.19 (q, 4H, 2 × CH₂), 3.74 (s, 3H, N-CH₃), 5.05 (s, 1H, Ar-H), 6.42 (s, 1H, -NH); MS (ESI) *m/z* 423.2 [M]⁺. Anal. Calcd for C₂₁H₃₀ClN₃O₄: C, 59.50; H, 7.13; N, 9.91. Found: C, 59.40; H, 7.02; N, 9.83%.

Diethyl-4-(2-butyl-4-chloro-1-(methylsulfonyl)-1H-imidazol-5-yl)-1-ethyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (3c)

White solid; yield 87%, m. p. 39 °C; IR: 3018-2855 cm⁻¹ (broad, -NH-), 1678 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, CDCl₃): δ_{ppm} 0.86-0.90 (t, 3H, -CH₃), 1.23-1.31 (t, 6H, 2 × CH₃), 1.33-1.37 (m, 2H, -CH₂), 1.62 (m, 2H, -CH₂), 2.32 (s, 6H, 2 × CH₃), 2.74 (t, 2H, Ar-CH₂), 2.82 (s, 3H, methyl sulfonyl), 4.19 (q, 4H, 2 × CH₂), 3.74 (s, 3H,

N-CH₃), 5.05 (s, 1H, Ar-H), 6.42 (s, 1H, -NH); MS (ESI) *m/z* 487.1 [M]⁺. Anal. Calcd for C₂₁H₃₀ClN₃O₆S: C, 51.69; H, 6.20; N, 8.61. Found: C, 60.22; H, 7.24; N, 9.48%.

Dimethyl-4-(2-butyl-4-chloro-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-di carboxylate (3d)


White solid; yield 88%, m. p. 220 °C; IR: 3333 cm⁻¹ (broad, -NH-), 1669 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, DMSO): δ_{ppm} 0.87-0.84 (t, 3H, -CH₃), 1.27 (m, 2H, -CH₂), 1.54 (m, 2H, -CH₂), 2.22 (s, 6H, 2Ar-CH₃), 2.48 (t, 2H, Ar-CH₂), 3.53 (s, 6H, 2 × O-CH₃), 4.90 (s, 1H, Ar-H), 8.89 (s, 1H, -NH), 11.46 (s, 1H, -NH); MS (ESI) *m/z* 381.2 [M]⁺. Anal. Calcd for C₁₈H₂₄ClN₃O₄: C, 56.62; H, 6.34; N, 11.00. Found: C, 56.51; H, 6.27; N, 10.81 %.

Dimethyl-4-(2-butyl-4-chloro-1-methyl-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylate (3e)

White solid; yield 86%, m. p. 49 °C; IR: 3022-2842 cm⁻¹ (broad, -NH-), 1682 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, DMSO): δ_{ppm} 0.86-0.83 (t, 3H, -CH₃), 1.28 (m, 2H, -CH₂), 1.54 (m, 2H, -CH₂), 2.24 (s, 6H, 2Ar-CH₃), 2.46 (q, 2H, Ar-CH₂), 3.54 (s, 6H, 2 × O-CH₃), 3.89 (s, 3H, N-CH₃), 4.91 (s, 1H, Ar-H), 8.91 (s, 1H, -NH); MS (ESI) *m/z* 395.1 [M]⁺. Anal. Calcd for C₁₉H₂₆ClN₃O₄: C, 57.64; H, 6.62; N, 10.61. Found: C, 57.53; H, 6.54; N, 10.49 %.

Dimethyl-4-(2-butyl-4-chloro-1-methylsulfinyl-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylate (3f)

White solid; yield 90%, m. p. 38°C; IR: 3018-2842 cm⁻¹ (broad, -NH-), 1682 cm⁻¹ (sharp, -CO-); ¹H NMR (400 MHz, DMSO): δ_{ppm} 0.88-0.85 (t, 3H, -CH₃), 1.29 (m, 2H, -CH₂), 1.56 (m, 2H, -CH₂), 2.24 (s, 6H, 2Ar-CH₃), 2.49 (q, 2H, Ar-CH₂), 2.64 (s, 3H, sulfonyl CH₃), 3.55 (s, 6H, 2 × O-CH₃), 4.91 (s, 1H, Ar-H), 8.92 (s, 1H, -NH); MS (ESI) *m/z* 459.1 [M]⁺. Anal. Calcd for C₁₉H₂₆ClN₃O₆S: C, 49.62; H, 5.70; N, 9.14. Found: Found: C, 49.52; H, 5.68; N, 9.02 %.



Scheme 1: Synthesis of title compounds: (i) PEG, corresponding Alkylating agents, 50°C, 15-30 min. (ii) L-Proline, ammonium carbonate, ethanol, room temperature for 4-5hr

RESULTS AND DISCUSSION

Chemistry

2-butyl-4-chloro-1*H*-imidazole-5-carbaldehyde (**1a**) on *N*-alkylation using PEG[13] as medium for 15-30 min at ambient temperature, resulting in the formation of *N*-alkyl-2-butyl-4-chloro-1*H*-imidazole-5-carbaldehydes (**1b-c**) in 90-92% yield. Latter on reaction with methyl/ethyl acetoacetate (**2**) and ammonium carbonate in the presence of L-proline in ethanol for 5 hr at room temperature resulted diethyl-4-(2-butyl-4-chloro-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (**3a-f**) in excellent yield 87-92% (**Table 1**).

Alternatively, **3(a-f)** could also be prepared in a one pot process by the reaction of *N*-alkyl-2-butyl-4-chloro-1*H*-imidazole-5-carbaldehydes (**1a-c**) with methyl/ethyl acetoacetate (**2**) and ammonium carbonate in the presence of catalytic amount of acetic acid in ethanol for 8-10 hr at refluxing temperature resulted the title compounds. This methodology required longer reaction time, poor yields and harsh conditions. The compounds thus obtained were found to be identical with **3(a-f)** obtained above in all respects. The compounds were characterized by IR, ¹H NMR and mass spectral techniques. Synthesis of above title compounds **3(a-f)** are shown in scheme-1.

CONCLUSION

In conclusion, a series of new chemical entities, diethyl/dimethyl 4-(2-butyl-4-chloro-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate **3(a-f)** have been synthesized. Instead conventional catalysts, we employed L-proline the preparation of diethyl/dimethyl 4-(2-butyl-4-chloro-1*H*-imidazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate **3(a-f)** with excellent yields and shorter reaction time.

Acknowledgement

The author (AJS) thankful to DST New Delhi and Technical Education Quality Improvement Programme (TEQIP) PHASE-II, Government of India for financial support.

REFERENCES

- [1] A. Hantzsch, Justus. Liebig's, *Ann.Chem.*, **1882**, 215, 182.
[2] (a) R. A. Janis, P. J. Silver, D. J. Triggler, *Adv.Drug.Res.*, **1987**, 16, 309; (b) P. P. Mager, R. A. Coburn, A. J. Solo, D. J. Triggler, H. Rothe, *Drug Des .Discov.*, **1992**, 8, 273; (c) R. Manmhold, B. Jablonka, W. Voigdt, K. Schoenafinger, E. Schraven, *J. Med. Chem.*, **1992**, 27, 229; (d) A. C. Gaudio, A. Korokovas, Y. Takahata, *J. Pharm. Sci.*, **1994**, 83, 1110.
[3] T. Godfraind, R. Miller, M. Wibo, *Pharmacol.Rev.*, **1986**, 38, 321.
[4] S. L. Bostrom, B. Ljung, S. Mardh, E. Thulin, *Nature.*, **1981**, 292, 777.
[5] J. E. Arrowsmith, S. F. Campbell, P. E. Cross, J. K. Stubbs, R. A. Burges, D. G. Gardiner, K.Blackburn, *J.med.chem.*,**1986**, 29, 1696.
[6] N. J. Rahway, The Merck Index, 12th edition, *Merck ResearchLaboratories.*, **1996**.
[7] Niloofar tavakoli-hoseini, *J. Chil. Chem. Soc.*,**2012**, 57, 1432-1435.
[8] L. M. Wang, J. Sheng, J. W. Zhang, J. W. Han, Z. Y. Fan, H. Tian, C. T. Qian, *Tetrahedron.*, **2005**, 61, 1539.
[9] S. sheik mansoor, K aswin, K logaiya, S. P N sudhan, *journal of king saud university-science.*,**2013**, 25,191-199.
[10] M. Maheswara, V. Siddaiah, Y.K. Rao, Y. M. Tzeng, C. Sridhar, *J. Mol. Catal. A .Chem.*, **2006**, 260, 179.
[11] K. Nandkishore, N. Gampawar, V. Sumit shinde, V. Sandeep jadhav, N. Wamanrao, *Chinese journal of Chemistry.*, **2007**, 25, 1686.
[12] P. Kotrusz, S. Toma, *Arkivoc.*, **2006**, (v), 100-109.
[13] A. V. Hanumantha Rao, P. N. Kishore Babu, V. Lakshman Rao, A. Jaya Shree, *Asian Journal of Chemistry.*, **2015**, 27, 1910.